In a Chinese study of the selective MET inhibitor savolitinib in patients with MET exon 14 skipping NSCLC, ORR in the 61 patients who were evaluable for efficacy was 47.5% (26). This evidence concerns the gene MET and non-small cell lung carcinoma.